112 results
Page 3 of 6
6-K
EX-99.1
3aftt76dw0byaxgvy0
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
ser8pnwh3k8e i0oug
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.2
iarezl
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
v5h805vz1haqe 8hl0i
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
g7p7ev34vi7d1
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
EX-99.2
u05yjtwj1v9a8sqzc
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
1pw2iuht6x8onkr838vr
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.2
c2sga 3xds5d0i4awd
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
v8goa44z7
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.3
qdrnaw
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
qhao06cl63bxv0ahci0
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.3
cfafha0xses
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
ao6l0j
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
fccdb98z4h0z ape
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
dofh1kdk
8 Jun 21
Current report (foreign)
7:30am
6-K
EX-99.2
wgew52u u51j3
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
7pfq7w62
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.3
wfhga98xryz cy
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
wqhi5x
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm